{"id":390285,"date":"2020-01-23T00:00:00","date_gmt":"2020-01-23T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0036-2020-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-adult-us-2020\/"},"modified":"2026-04-14T10:25:12","modified_gmt":"2026-04-14T10:25:12","slug":"algoim0036-2020-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-adult-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0036-2020-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-adult-us-2020\/","title":{"rendered":"Crohn&#8217;s Disease | Treatment Algorithms: Claims Data Analysis | Adult | US | 2020"},"content":{"rendered":"<p>Crohn\u2019s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and\/or biologics. However, this scenario is changing, and more physicians are prescribing biologics as first-line therapy for recently diagnosed CD patients. Among the biologics, TNF-alpha inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira) have a relatively constant patient share; however, newer biologics (e.g., Takeda\u2019s Entyvio, Janssen\u2019s Stelara), especially Stelara, have witnessed a sharp increase in\u00a0patient share.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>\u00a0What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult\u00a0CD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult\u00a0CD\u00a0patients?<\/li>\n<li>How have Entyvio and Stelara been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of adult\u00a0CD\u00a0patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of adult\u00a0CD\u00a0patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geographies<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>Real World Data<\/strong><\/p>\n<p>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key Drugs Covered<\/strong><\/p>\n<p>Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants<\/p>\n<p><strong>Key Analysis <\/strong><strong>Provided <\/strong><\/p>\n<ul>\n<li>Brand\/therapy usage across longitudinal patient sample<\/li>\n<li>Newly diagnosed patient analysis<\/li>\n<li>Treatment initiation and progression<\/li>\n<li>Line of therapy analysis<\/li>\n<li>Combination therapy analysis<\/li>\n<li>Source of business for recently treated patients<\/li>\n<li>Persistency and compliance analysis<\/li>\n<li>Product-level patient flowcharts<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n","protected":false},"template":"","class_list":["post-390285","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390285\/revisions"}],"predecessor-version":[{"id":393410,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390285\/revisions\/393410"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}